INTERACTION
ID	lncRNA Name	Interaction target	Level of interaction	Type of interaction	Description	PMID	Source
EL0861	MEG3	cAMP	DNA-TF	regulation	Deletion and mutation analysis suggest that a cAMP response element (CRE), located between -69 and -49 of the MEG3 proximal promoter region, is critical for promoter activity. Furthermore, gel shifting, ChIP analysis, and co-transfection experiments show that CREB directly binds to the CRE site and stimulates MEG3 promoter activity. Therefore, MEG3 is a downstream target gene of cAMP.	16793321	LncRNADisease
EL0861	MEG3	GDF15	RNA-DNA	regulation	We further found that MEG3 stimulates expression of the growth differentiation factor 15 (GDF15) by enhancing p53 binding to the GDF15 gene promoter.	17569660	LncRNADisease
EL0861	MEG3	p53	RNA-Protein	binding	We further found that MEG3 stimulates expression of the growth differentiation factor 15 (GDF15) by enhancing p53 binding to the GDF15 gene promoter.	17569660	LncRNADisease
EL0861	MEG3	p53	RNA-RNA	co-expression	MEG3 functions to suppress tumor cell growth, increase protein expression of the tumor suppressor p53, and selectively activate p53 target genes.	20211686	LncRNADisease
EL0861	MEG3	p53	RNA-Protein	regulation	The lncRNA MEG3 is a positive regulator of p53.	20951849	LncRNADisease
EL0861	MEG3	Tp53	RNA-DNA	regulation	The lncRNA MEG3 activates the expression of Tp53 and enhances its binding affinity to the promoter of its target gene.	21247874	LncRNADisease
EL0861	MEG3	p53	RNA-DNA	regulation	Putative tumour suppressor. Regulates p53 expression. Inhibits cell proliferation in the absence of p53.	21256239	LncRNADisease
EL0861	MEG3	cAMP response element-binding protein	DNA-Protein	binding	We show that menin activates the long noncoding RNA maternally expressed gene 3 (Meg3) by histone-H3 lysine-4 trimethylation and CpG hypomethylation at the Meg3 promoter CRE site, to allow binding of the transcription factor cAMP response element-binding protein.	25565142
EL0861	MEG3	osterix, osteocalcin, BMP4	RNA-Protein	regulation	We observed that MEG3 knockdown significantly reduced the expression of key osteogenic markers, including Runt-related transcription factor 2, osterix, and osteocalcin, while overexpression of MEG3 enhanced their expression. Additionally, MEG3 knockdown decreased BMP4 transcription. Here we showed that MEG3 was critical for SOX2 transcriptional repression of the BMP4.	25753650
EL0861	MEG3	p53 and Bcl-xl	RNA-DNA	co-expression	MEG3 is significantly downregulated in LAD and partially regulates the cisplatin resistance of LAD cells through the control of p53 and Bcl-xl expression. Thus, MEG3 may represent a new marker of poor response to cisplatin and could be a potential therapeutic target for LAD chemotherapy	25992654
EL0861	MEG3	Rac1	RNA-DNA	regulation	we also showed that Rac1 was negatively regulated by lncRNA-MEG3 at the posttranscriptional level, via a specific target site within the 3΄UTR by dual luciferase reporter assay. The expression of Rac1 was inversely correlated with lncRNA-MEG3 expression in PTC tissues. Thus, this study suggests that MEG3 acts as novel suppressor of migration and invasion by targeting Rac1 gene.	25997963
EL0861	MEG3	Bcl-2	RNA-RNA	regulation	Bcl-2 mRNA level was declined by MEG3 overexpression.	26223924
EL0861	MEG3	MiR-141	RNA-RNA	regulation	Mir-141 inhibits gastric cancer proliferation by interacting with long noncoding RNA meg3 and down-regulating e2f3 expression.	26233544
EL0861	MEG3	Bcl-2	RNA-Protein	regulation	MEG3 could up-regulated Bcl-2 via its competing endogenous RNA (ceRNA) activity on miR-181a.	26253106
EL0861	MEG3	miR-181 s	RNA-RNA	regulation	MEG3 sequestering oncogenic miR-181 s in GC cells.	26253106
EL0861	MEG3	p53	RNA-Protein	regulation	In addition, inactivation of p53 completely abolished tumor suppression by MEG3, indicating that MEG3 tumor suppression is mediated by p53.	26284494
EL0861	MEG3	miR-21	RNA-RNA	regulation	Overexpression of MEG3 reduced the level of miR-21-5p expression.	26574780
EL0861	MEG3	FoxO1, G6pc, Pepck	RNA-DNA	regulation	MEG3 overexpression significantly increased FoxO1, G6pc, Pepck mRNA expressions and hepatic gluconeogenesis and suppressed insulin-stimulated glycogen synthesis in primary hepatocytes, whereas palmitate-induced increase of FoxO1, G6pc and Pepck protein expressions could be reversed by MEG3 interference.	26603935
EL0861	MEG3	Bcl-2, Bax, activating caspase 3, Cyclin D1	RNA-Protein	regulation	MEG3 inhibited intrinsic cell survival pathway in vitro and in vivo by reducing the protein expression of Bcl-2, enhancing Bax and activating caspase 3. MEG3 inhibited the expression of cell cycle regulatory protein Cyclin D1 and induced cell cycle arrest in G0/G1 phase.	26610246
EL0861	MEG3	p53, caspase-3, MDM2 and cyclin D1,	RNA-Protein	regulation	Ectopic expression of MEG3 increased p53, caspase-3 mRNA and protein levels, decreased MDM2 and cyclin D1 mRNA and protein levels, as well as ILF3 protein expression in HepG2 cells.	26647875
EL0861	MEG3	ILF3	RNA-Protein	regulation	ILF3 may participate in the anticancer regulation of MEG3 by interacting with MEG3.	26647875
EL0861	MEG3	DNMT1	DNA-Protein	regulation	DNMT1 was involved in MEG3 promoter methylation, and was inversely correlated with MEG3 expression in gliomas. DNMT1-mediated MEG3 hypermethylation caused the loss of MEG3 expression, followed by the inhibition of the p53 pathways in gliomas.	26676363
EL0861	MEG3	IFN-γ	DNA-Protein	regulation	IFN-γ induced autophagy in infected macrophages resulted in sustained MEG3 down regulation and lack of IFN-γ allowed for counter regulation of MEG3 by viable M. bovis BCG.	26757825
EL0861	MEG3	miR-140-5p	RNA-RNA	regulation	Pioglitazone up-regulated MEG3 expression to protect EPCs via decreasing miR-140-5p expression and increasing HDAC7 expression in MetS	26898430